Prelude Therapeutics (PRLD) Stock Statistics & Valuation Metrics

Prelude Therapeutics has a market cap or net worth of $99.61M. The enterprise value is $6.21M.

Prelude Therapeutics has 43,744,064 shares outstanding. The number of shares has decreased by -2.65% in one year.

Prelude Therapeutics’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -89.98%.

The current PE Ratio of Prelude Therapeutics is ―. Prelude Therapeutics’s PEG ratio is 0.04.

In the last 12 months, Prelude Therapeutics had revenue of 7.00M and earned -127.17M in profits. Earnings per share was -1.68.

In the last 12 months, operating cash flow was -100.17M and capital expenditures -120.00K, giving a free cash flow of -100.28M billion.

Prelude Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Prelude Therapeutics upcoming earnings date is Mar 18, 2026, Before Open (Confirmed).

Prelude Therapeutics as a current ratio of 5.30, with Debt / Equity ratio of 23.63%

In the past 12 months, Prelude Therapeutics has paid 0.00 in taxes.

Prelude Therapeutics EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.73.

Prelude Therapeutics has $54.96M in cash and marketable securities with $17.85M in debt, giving a net cash position of $37.10M billion.

Gross margin is 87.60%, with operating margin of -1995.91%, and net profit margin of -1816.76%.

The average price target for Prelude Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy